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Introduction
Mild cognitive impairment (MCI) is considered a transi-
tional stage between normal aging and dementia, in par ti-
cular Alzheimer’s disease (AD) [1]. Th e rate of conversion 
from MCI to AD is approximately 15% per year [2]. 
However, a substantial number of MCI patients have 
cognitive complaints caused by other conditions, such as 
depression, stress, or sleeping disorders. It is important, 
therefore, for clinicians to identify individuals who are in 
the prodromal stage of AD, in particular because these 
patients may be a target for future disease-modifying 
treatments. Advanced neuroimaging tech niques may 
improve diagnostic accuracy in this patient group. Th e 
positron emission tomography (PET) ligand 11C labeled 
Pittsburgh compound-B ([11C]PIB) [3] detects ﬁ brillary 
amyloid-beta (Aβ) in vivo, and may be used for this 
purpose. [11C]PIB PET discriminates well between AD 
and controls [3,4] and between AD and other types of 
dementia [5], with the exception of dementia with Lewy 
bodies [6]. In patients with MCI, little is known about the 
predictive value of [11C]PIB PET for progression to AD, 
or about temporal changes in [11C]PIB binding.
Recently, Koivunen and colleagues [7] reported the 
results of a prospective 2-year follow-up study in which 
they assessed the predictive value of [11C]PIB PET for 
pro gression to AD as well as the temporal changes in 
amyloid deposition in MCI patients. In the present 
commentary, we discuss the ﬁ ndings of this study and its 
potential implications for future clinical trials with 
disease-modifying agents in prodromal AD.
Identifying prodromal AD with [11C]PIB PET
Koivunen and colleagues [7] performed amyloid imaging 
with [11C]PIB PET at baseline and after 2 years of follow-
up in a sample of 29 MCI patients. Th ey divided MCI 
patients into converters and non-converters, based on 
clinical diagnosis at follow-up. At baseline, MCI con-
verters had substantially higher mean [11C]PIB levels 
com pared to MCI non-converters in the posterior cingu-
late, lateral frontal and temporal cortices and in putamen 
and caudate nucleus. After classifying [11C]PIB PET scans 
into either positive or negative, using a cut-oﬀ  point of 
1.5 standardized uptake value ratio (SUVr), 21 of 29 
(72%) subjects with MCI had a positive [11C]PIB PET 
scan. In their study, 15 of the 21 (71%) [11C]PIB-positive 
MCI patients progressed to AD while only 1 out of 8 
(12.5%) [11C]PIB-negative MCI patients did so. Th ese 
results are in accordance with several previous studies 
[8,9] and indicate that [11C]PIB PET predicts progression 
to AD in MCI patients.
Abstract
Patients with mild cognitive impairment are at an 
increased risk of progression to Alzheimer’s disease. 
However, not all patients with mild cognitive 
impairment progress, and it is diffi  cult to accurately 
identify those patients who are in the prodromal stage 
of Alzheimer’s disease. In a recent paper, Koivunen 
and colleagues report that Pittsburgh compound-B, 
an amyloid-beta positron emission tomography 
ligand, predicts the progression of patients with mild 
cognitive impairment to Alzheimer’s disease. Of 29 
subjects with mild cognitive impairment, 21 (72%) had 
a positive Pittsburgh compound-B positron emission 
tomography baseline scan. In their study, 15 of these 
21 (71%) patients progressed to Alzheimer’s disease, 
whilst only 1 out of 8 (12.5%) Pittsburgh compound-
B-negative patients with mild cognitive impairment 
did so. Moreover, in these mild cognitive impairment 
patients, the overall amyloid burden increased 
approximately 2.5% during the follow-up period. This 
is consistent with other longitudinal amyloid imaging 
studies that found a similar increase in amyloid 
deposition over time in patients with mild cognitive 
impairment. These studies together challenge current 
theories that propose a fl attening of the increase of 
brain amyloid deposition already in the preclinical 
stage of Alzheimer’s disease. These fi ndings may have 
important implications for the design of future clinical 
trials aimed at preventing progression to Alzheimer’s 
disease by lowering the brain amyloid-beta burden in 
patients with mild cognitive impairment.
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Temporal changes in amyloid burden in MCI
Recently, Jack and colleagues [10] proposed a hypo-
thetical model that positioned established and novel 
biomarkers in the continuum of AD. Th is model elabor-
ates on the amyloid-cascade hypothesis [11], which states 
that accumulation of Aβ initiates a cascade of neuro-
pathological events, such as the formation of neuroﬁ bril-
lary tangles and neuroinﬂ ammation. Th is may in turn 
lead to neurodegeneration that presumably is followed by 
cognitive deterioration and ﬁ nally results in dementia. 
Accumulation of Aβ is thought to set in decades before 
the ﬁ rst cognitive complaints arise, starts to accelerate 
already in the preclinical stage of AD, and reaches a 
relative plateau at the time symptoms emerge [12].
In the study by Koivunen and colleagues, the overall 
amyloid burden in MCI patients increased approximately 
2.5% in 2 years. Th is increase was most prominent for 
those patients who did not convert to AD. However, the 
overall increase in amyloid deposition was only modest, 
whilst hippocampal volumes decreased more strongly. 
Th is is in line with the idea that Aβ starts oﬀ  the cascade 
and may uncouple at a later time point from neuro-
degenerative processes. Previous studies that related the 
presence of amyloid plaques with the course of brain 
atrophy [13] and glucose hypometabolism [14] also found 
this dissociation between amyloid deposition and struc-
tural and functional changes. Th e ﬁ ndings of Koivunen 
and colleagues suggest that the time span between 
deposition of amyloid and actual neurodegeneration may 
perhaps be shorter than previously assumed, given the 
dynamic Aβ changes in MCI patients in this study.
Th e ﬁ nding of increased amyloid burden over time in 
MCI patients is consistent with other recent longitudinal 
amyloid imaging studies. Villemagne and colleagues [15] 
reported that 65 MCI patients had a mean increase in 
[11C]PIB retention of 2.1% over a 20-month follow-up 
period (annual increase of 1.3%). A study by Jack and 
colleagues [16] showed an annual increase of 1.7% in 32 
MCI patients. Moreover, in an unpublished study from 
our group in 12 MCI patients, [11C]PIB binding increased 
by 5.0% over a 30-month period (annual increase 2%). 
Th ese results are in accordance with the 2.5% increase 
over 24 months (annual increase 1.25%) reported by 
Koivunen and colleagues. In all these longitudinal 
studies, the increased amyloid burden was primarily 
driven by MCI patients that displayed high [11C]PIB 
retention at baseline. Taken together, amyloid deposition 
seems to increase in both MCI converters and non-
converters, thereby challenging the theory that amyloid 
plaque load is stable in the prodromal stage of AD.
A limitation of the study by Koivunen and colleagues, 
especially given its longitudinal design, is the use of SUVr, 
which overestimates [11C]PIB binding in compari son with 
fully quantitative kinetic models [17]. Further more, SUVr 
does not correct for factors that are inherently associated 
with disease progression, such as hetero geneous ﬂ ow 
eﬀ ects in the region of interest compared to the reference 
region. We therefore argue that quantitative modeling, 
and thus dynamic PET scanning, is essential for 
longitudinal amyloid imaging studies.
Amyloid imaging in clinical trials
Th e ﬁ nding that [11C]PIB PET can help identify 
prodromal AD patients and that most MCI patients show 
an increased amyloid burden over time may have 
implications for the design of future clinical trials. First of 
all, amyloid imaging may be used as an enrichment 
strategy by enabling the selection of subjects at risk for 
AD, in order to administer disease-modifying agents to 
the right patients. Secondly, Aβ PET ligands may be used 
as a secondary outcome measure to provide biological 
insight into cognitive primary outcome measures. Finally, 
amyloid imaging can be applied as a surrogate outcome 
measure to test whether anti-amyloid therapies are 
eﬃ  cacious by measuring the amount of ﬁ brillary Aβ 
prior to and after the time window of the intervention. In 
this respect one should note that patients with prodromal 
AD may still show an increase in amyloid plaque forma-
tion, instead of the previously assumed plateau due to an 
equilibrium between production and clearance of Aβ. 
Th is will aﬀ ect power calculations for such trials. Current 
development of several ﬂ uor-18-labeled amyloid PET 
tracers (which have a longer half-life time compared to 
carbon-11) will further increase the availability and 
applicability of amyloid imaging in both clinical practice 
and for scientiﬁ c purposes.
Conclusion
Koivunen and colleagues showed that amyloid imaging 
may be used to predict clinical progression to AD in 
patients with MCI and that, contrary to current hypo-
thetical biomarker models, amyloid deposition increases 
over time in patients with MCI. Th ese ﬁ ndings are 
relevant for the design of future clinical trials aimed at 
the prevention of progression to AD by lowering the Aβ 
burden in the brains of patients with MCI.
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